This audio is automatically generated. Do us know if you have comments.
Brief of diving:
- Roche is the last drug planning to expand the production of medicines in the United States, announcing on Tuesday a commitment to spend $ 50 billion in five years in new and existing manufacturing facilities in several states.
- The investment promise comes at a time when Trump Administration’s fare policies have launched world trade in disorder and have pressured drug makers. Roche, in response, said he intends to build new factories for obesity medicine, gene therapies, continuous glucose control devices, as well as a new research and development center. Roche will also expand several existing plants.
- According to Roche, investments will allow the company to export more medicines in the United States than to the diagnostics. They will also create 12,000 new jobs, the company said.
Divide vision:
Roche is the fifth major drug maker this year to promise significantly increase his north -American manufacturing capacity, following Johnson & Johnson, Eli Lilly, Merck & Co. and Novartis. All in all, the five have committed more than $ 160 million to US drug production in the coming years.
Roche’s departure will create a series of new plants, such as a gene therapy installation in Pennsylvania and a Ai -centered R&D center in Massachusetts. It would also finance expansions and updates for existing facilities that manufacture medicines and diagnostics. These plants are found in Kentucky, Indiana, New Jersey, Oregon, Arizona and California.
“Today’s investments are highlighted by our commitment to research, development and manufacturing in the United States,” said Thomas Schinecker, CEO of Roche, in a statement. “We are proud of our 110 -year legacy in the United States, which has been a key engine for jobs, innovation and intellectual property creation in the United States, both in our pharmaceutical and diagnostic divisions.”
Pharmaceutical companies face the possibility of new Trump Administration’s rates that could be implemented in the coming weeks. Administration senior officials believe that they can use taxes to push drug manufacturers to manufacture pharmaceuticals and their key ingredients.
Roche and his companions are trying to advance these threats announcing new North -American investments. However, it could happen several years before many of these new facilities are completed and have a measurable impact on medicine imports.
In 2024, Roche sold a biological plant in Vacville, California, to the Lonza Swiss Contract Manufacturer for $ 1.2 billion. In general, the company registered 827 million Swiss francs, or $ 940 million, cost -related costs in 2024. As comparatively, Roche spent 1.7 billion Swiss francs on property, plants and equipment for their pharmaceutical division and 1.8 billion Swiss francs at these costs for their diagnostic businesses.
